Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous Melanoma
Caroline Robert(Institut Gustave Roussy), Dirk Schadendorf(National Center for Tumor Diseases), Kamil Drucis(Apple (Israel)), Jeffrey J. Legos(Novartis (United States)), Jacob Schachter, Andrzej Maćkiewicz(Poznan University of Medical Sciences), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), M. Lichinitser(Apple (Israel)), Peng Sun(Philips (Finland)), Wendy Crist(Apple (Israel)), Axel Hauschild(University Hospital Schleswig-Holstein), Florent Grange(Hôpital Lyon Sud), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Laurent Mortier, Bogusława Karaszewska(State University of Applied Sciences in Konin), Reinhard Dummer(University Hospital of Zurich), D. Stroiakovski(Moscow City Oncology Hospital №62), Ivana Krajsová(Charles University), S. D. Rubin(GlaxoSmithKline (United States)), Shonda M Little(Apple (Israel))
Cited by 7
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k